

**Embargoed for Release**  
**Sunday, 18 July 2010**  
**11:15 am Central European Time**

**Contact**  
Mark Aurigemma  
[mark@aucomm.net](mailto:mark@aucomm.net)  
+1 (212) 600-1960 (office)  
+1 (646) 270-9451 (mobile)

**GLOBAL HIV VACCINE ENTERPRISE RELEASES NEW OVERVIEW OF THE  
GREATEST CHALLENGES AND OPPORTUNITIES IN HIV VACCINE RESEARCH  
AT AIDS 2010 CONFERENCE**

***The Road to Prevention* Outlines Key Recommendations  
to Speed the Search for an HIV Vaccine**

(Vienna, Austria) – The Global HIV Vaccine Enterprise, a unique alliance of independent organizations dedicated to accelerating the development of a preventive HIV vaccine, today released a new overview of the major obstacles to developing the safe and effective vaccines that could one day help end the AIDS epidemic. The document, *The Road to Prevention*, also contains clear recommendations to accelerate HIV vaccine research and identifies opportunities to make the field more dynamic, collaborative and efficient moving forward.

“Since its creation, the collaborative efforts of Global HIV Vaccine Enterprise stakeholders have led to significant changes in how HIV vaccine research has been focused, organized and funded, and have helped produce major breakthroughs in the field,” said Peter Piot, Director of the Institute for Global Health at Imperial College, London. “*The Road to Prevention* presents a timely overview of the biggest challenges we face now in translating those advances into real progress toward the development of safe and effective HIV vaccines.”

Among the issues addressed in the “The Road to Prevention” are the need to:

- Build aggressively on recent laboratory and clinical trial advances
- Increase rapid data sharing among HIV vaccine researchers and between research efforts
- Expand efforts to attract new minds and new ideas to the HIV vaccine research endeavor
- Broaden funding sources and increase funding levels for HIV vaccine research

“The Road to Prevention” is being released in advance of the launch of the Global HIV Vaccine Enterprise Scientific Strategic Plan, the plan of the Enterprise Council and a collaborative effort of more than 400 researchers worldwide, which will be released at the AIDS Vaccine 2010 conference in Atlanta, USA in September.

- continued -

“The search for a safe and effective HIV vaccine remains one of the great challenges for modern science,” said Global HIV Vaccine Enterprise Executive Director, Alan Bernstein. “At the same time, recent scientific advances, including the first evidence that an HIV vaccine can partially protect against HIV infection, along with improved collaboration and information sharing in the field, have brought us to a new era in HIV vaccine research – one that presents new opportunities to re-think and re-focus efforts to develop the safe and effective vaccines that can help end this epidemic.”

“Breakthroughs in HIV vaccine research are achievable if we work together to aggressively pursue the best science,” said Jose Esparza, senior advisor for HIV vaccines at the Bill & Melinda Gates Foundation. “We need to learn all we can from the HIV vaccine candidates currently being tested, and encourage creative new thinking from the world’s top scientists.”

“No one researcher or research group is going to develop an HIV vaccine on their own,” said Rwandan First Lady and former African AIDS Vaccine Programme High Representative Mme. Jeannette Kagame. “All parts of the world must be part of the solution. Africans have a key role to play the global collaboration working to develop an HIV vaccine. The recommendations in *The Road to Prevention* are key to achieving that strategic collaboration.”

#### About the Global HIV Vaccine Enterprise

The Global HIV Vaccine Enterprise is a unique alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine. The Enterprise, comprised of top research, funding, advocacy and other stakeholder organizations, develops and drives implementation of the Scientific Strategic Plan for HIV vaccine development. Enterprise stakeholders set shared research agendas, create new structures for information sharing, develop new tools to harmonize global research efforts, and bring new organizations, expertise and resources to the challenge. For more information, please visit [www.vaccineenterprise.org](http://www.vaccineenterprise.org).

###